Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit - Full Text View

Sponsored by:	University of Pittsburgh
Information provided by:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00177931

Purpose

The purposes of this study are to:

I. Characterize the plasma concentration-time profile of cefepime in liver transplant patients to determine the pharmacokinetic parameters in this patient population.

II. Perform stochastic modeling using the population pharmacokinetic parameters obtained in Specific Aim I to determine the ideal dose and dosing regimen of cefepime required to attain predetermined therapeutic targets in liver transplant patients.

Condition
Liver Transplantation

MedlinePlus related topics: Liver Transplantation

Drug Information available for: Cefepime Cefepime hydrochloride

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit

Further study details as provided by University of Pittsburgh:

Biospecimen Retention: Samples Without DNA

Biospecimen Description:

All biologic samples will be under the control of the principal investigator of this research project. To protect confidentiality, all personal identifiers will be removed and replaced with a specific code number. The information linking these code numbers to the corresponding subjects' identities will be kept in a separate, secure location. The investigators on this study will keep the samples indefinitely. All samples will be provided to investigators not associated with the study without any identifiers and only contain a code number. If a subject withdraws samples collected and not already processed will be destroyed.

Estimated Enrollment:	25
Study Start Date:	March 2005
Estimated Study Completion Date:	December 2009

Groups/Cohorts
liver transplant patients in ICU

Detailed Description:

The use of cefepime in liver transplant patients at conventional doses used for other patient populations leads to non-optimal drug exposure among liver transplant patients. Furthermore, using serum creatinine as a method of estimating creatinine clearance is not the optimal way to determine the best cefepime dose. The consequence of this non-optimal exposure is the unattainability of therapeutic targets. These therapeutic targets are correlated with positive microbiologic outcome and clinical cure.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Liver transplant patients in the ICU

Criteria

Inclusion Criteria:

Women and members of minority groups will be included in this study. However, as this study seeks to generate pilot data, there will be no specific statistical analysis comparing differences based on gender or race.
Subjects receiving drugs known to induce or inhibit hepatic enzymes are not excluded from this study as cefepime is renally eliminated and not significantly metabolized by the liver.
All liver transplant subjects are eligible for enrollment in this study, including subjects who have undergone a living related liver transplant.
The pharmacokinetics of cefepime in children are significantly different from those of adults. For the purposes of this study only adults (aged > 18 years old) will be able to participate.

Exclusion Criteria:

Subjects will be excluded if they are anemic (hemoglobin < 7 mg/dl), or are patients with severe gastrointestinal bleeding who are receiving packed red blood cells.
Subjects who are receiving hemodialysis or other forms of renal replacement therapy (such as continuous veno-venous hemofiltration), or patients with a calculated creatinine clearance of < 10 ml/min will be excluded from the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00177931

Contacts

Contact: Brian Potoski, PharmD	412-648-6401	potoba@upmc.edu
Contact: Diana Pakstis, RN, BSN	412-648-6401	pakstisdl@dom.pitt.edu

Locations

United States, Pennsylvania
University of Pittsburgh Medical Center	Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Brian Potoski, PharmD 412-648-6401 potoba@upmc.edu
Contact: Diana Pakstis, RN, BSN 412-648-6401 paksdl@dom.pitt.edu
Principal Investigator: Brian Potoski, PharmD

Sponsors and Collaborators

University of Pittsburgh

Investigators

Principal Investigator:

Brian Potoski, PharmD

University of Pittsburgh

More Information

Responsible Party:	UPMC ( Brian Potoski, Pharm D )
Study ID Numbers:	IRB # 0403014
Study First Received:	September 13, 2005
Last Updated:	December 16, 2008
ClinicalTrials.gov Identifier:	NCT00177931
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Pittsburgh:

Liver transplant
cefepime
antibiotics

Study placed in the following topic categories:

Cefepime

Additional relevant MeSH terms:

Anti-Infective Agents
Anti-Bacterial Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009